Medical - Instruments & Supplies
Compare Stocks
5 / 10Stock Comparison
RMD vs PHG vs SYK vs BSX vs MDT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Devices
Medical - Devices
Medical - Devices
RMD vs PHG vs SYK vs BSX vs MDT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Devices | Medical - Devices | Medical - Devices | Medical - Devices |
| Market Cap | $30.15B | $25.84B | $112.69B | $84.08B | $99.94B |
| Revenue (TTM) | $5.54B | $17.83B | $25.12B | $20.07B | $35.48B |
| Net Income (TTM) | $1.52B | $895M | $3.25B | $2.89B | $4.61B |
| Gross Margin | 61.7% | 45.2% | 63.5% | 69.0% | 61.9% |
| Operating Margin | 34.3% | 8.0% | 22.4% | 19.8% | 17.9% |
| Forward P/E | 18.8x | 17.5x | 19.6x | 16.7x | 14.1x |
| Total Debt | $852M | $8.09B | $14.86B | $12.42B | $28.52B |
| Cash & Equiv. | $1.21B | $2.79B | $4.01B | $2.04B | $2.22B |
RMD vs PHG vs SYK vs BSX vs MDT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| ResMed Inc. (RMD) | 100 | 128.7 | +28.7% |
| Koninklijke Philips… (PHG) | 100 | 65.9 | -34.1% |
| Stryker Corporation (SYK) | 100 | 150.3 | +50.3% |
| Boston Scientific C… (BSX) | 100 | 148.9 | +48.9% |
| Medtronic plc (MDT) | 100 | 79.1 | -20.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RMD vs PHG vs SYK vs BSX vs MDT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
RMD has the current edge in this matchup, primarily because of its strength in long-term compounding and valuation efficiency.
- 293.8% 10Y total return vs SYK's 187.1%
- PEG 1.08 vs MDT's 36.00
- Better valuation composite
- 27.4% margin vs PHG's 5.0%
PHG is the clearest fit if your priority is momentum.
- +17.7% vs BSX's -46.0%
Among these 5 stocks, SYK doesn't own a clear edge in any measured category.
BSX is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 19.9%, EPS growth 55.2%, 3Y rev CAGR 16.5%
- Lower volatility, beta 0.34, Low D/E 50.7%, current ratio 1.62x
- 19.9% revenue growth vs PHG's -1.0%
- Beta 0.34 vs PHG's 1.12, lower leverage
MDT ranks third and is worth considering specifically for income & stability and defensive.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Beta 0.47, yield 3.6%, current ratio 1.85x
- 3.6% yield, 36-year raise streak, vs PHG's 1.5%, (1 stock pays no dividend)
- 175.8% ROA vs PHG's 3.4%, ROIC 6.0% vs 6.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.9% revenue growth vs PHG's -1.0% | |
| Value | Better valuation composite | |
| Quality / Margins | 27.4% margin vs PHG's 5.0% | |
| Stability / Safety | Beta 0.34 vs PHG's 1.12, lower leverage | |
| Dividends | 3.6% yield, 36-year raise streak, vs PHG's 1.5%, (1 stock pays no dividend) | |
| Momentum (1Y) | +17.7% vs BSX's -46.0% | |
| Efficiency (ROA) | 175.8% ROA vs PHG's 3.4%, ROIC 6.0% vs 6.4% |
RMD vs PHG vs SYK vs BSX vs MDT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
RMD vs PHG vs SYK vs BSX vs MDT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
RMD leads in 2 of 6 categories
PHG leads 2 • MDT leads 1 • SYK leads 0 • BSX leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
RMD leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 6.4x RMD's $5.5B. RMD is the more profitable business, keeping 27.4% of every revenue dollar as net income compared to PHG's 5.0%. On growth, BSX holds the edge at +15.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $5.5B | $17.8B | $25.1B | $20.1B | $35.5B |
| EBITDAEarnings before interest/tax | $2.1B | $2.5B | $6.3B | $4.7B | $9.4B |
| Net IncomeAfter-tax profit | $1.5B | $895M | $3.2B | $2.9B | $4.6B |
| Free Cash FlowCash after capex | $1.8B | $755M | $4.3B | $3.6B | $5.4B |
| Gross MarginGross profit ÷ Revenue | +61.7% | +45.2% | +63.5% | +69.0% | +61.9% |
| Operating MarginEBIT ÷ Revenue | +34.3% | +8.0% | +22.4% | +19.8% | +17.9% |
| Net MarginNet income ÷ Revenue | +27.4% | +5.0% | +12.9% | +14.4% | +13.0% |
| FCF MarginFCF ÷ Revenue | +31.7% | +4.2% | +17.1% | +18.1% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.8% | +1.1% | +11.4% | +15.9% | +8.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +9.3% | +2.1% | +56.0% | +18.5% | -11.9% |
Valuation Metrics
PHG leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, MDT trades at a 38% valuation discount to SYK's 35.0x P/E. Adjusting for growth (PEG ratio), RMD offers better value at 1.25x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $30.1B | $25.8B | $112.7B | $84.1B | $99.9B |
| Enterprise ValueMkt cap + debt − cash | $29.8B | $32.1B | $123.5B | $94.5B | $126.2B |
| Trailing P/EPrice ÷ TTM EPS | 21.76x | 24.85x | 35.03x | 29.16x | 21.60x |
| Forward P/EPrice ÷ next-FY EPS est. | 18.78x | 17.55x | 19.62x | 16.75x | 14.13x |
| PEG RatioP/E ÷ EPS growth rate | 1.25x | — | 2.36x | — | 36.00x |
| EV / EBITDAEnterprise value multiple | 15.51x | 10.70x | 20.31x | 25.30x | 14.32x |
| Price / SalesMarket cap ÷ Revenue | 5.86x | 1.23x | 4.49x | 4.19x | 2.98x |
| Price / BookPrice ÷ Book value/share | 5.11x | 2.02x | 5.02x | 3.46x | 2.08x |
| Price / FCFMarket cap ÷ FCF | 18.14x | 24.62x | 26.31x | 22.99x | 19.28x |
Profitability & Efficiency
RMD leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
RMD delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $8 for PHG. RMD carries lower financial leverage with a 0.14x debt-to-equity ratio, signaling a more conservative balance sheet compared to PHG's 0.74x. On the Piotroski fundamental quality scale (0–9), RMD scores 8/9 vs MDT's 6/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +24.4% | +8.2% | +15.0% | +12.4% | +9.4% |
| ROA (TTM)Return on assets | +18.0% | +3.4% | +6.9% | +6.9% | +175.8% |
| ROICReturn on invested capital | +22.8% | +6.4% | +11.4% | +8.8% | +6.0% |
| ROCEReturn on capital employed | +25.7% | +7.1% | +13.0% | +11.1% | +7.5% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 7 | 6 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.14x | 0.74x | 0.66x | 0.51x | 0.59x |
| Net DebtTotal debt minus cash | -$358M | $5.3B | $10.8B | $10.4B | $26.3B |
| Cash & Equiv.Liquid assets | $1.2B | $2.8B | $4.0B | $2.0B | $2.2B |
| Total DebtShort + long-term debt | $852M | $8.1B | $14.9B | $12.4B | $28.5B |
| Interest CoverageEBIT ÷ Interest expense | 66.06x | 4.34x | 6.72x | 11.03x | 9.08x |
Total Returns (Dividends Reinvested)
PHG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BSX five years ago would be worth $13,117 today (with dividends reinvested), compared to $5,734 for PHG. Over the past 12 months, PHG leads with a +17.7% total return vs BSX's -46.0%. The 3-year compound annual growth rate (CAGR) favors PHG at 11.6% vs RMD's -2.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -15.2% | +0.3% | -15.2% | -40.3% | -18.1% |
| 1-Year ReturnPast 12 months | -14.5% | +17.7% | -22.5% | -46.0% | -2.8% |
| 3-Year ReturnCumulative with dividends | -8.4% | +38.8% | +5.5% | +6.5% | -4.2% |
| 5-Year ReturnCumulative with dividends | +11.0% | -42.7% | +21.5% | +31.2% | -27.7% |
| 10-Year ReturnCumulative with dividends | +293.8% | +48.3% | +187.1% | +155.5% | +26.5% |
| CAGR (3Y)Annualised 3-year return | -2.9% | +11.6% | +1.8% | +2.1% | -1.4% |
Risk & Volatility
Evenly matched — PHG and BSX each lead in 1 of 2 comparable metrics.
Risk & Volatility
BSX is the less volatile stock with a 0.34 beta — it tends to amplify market swings less than PHG's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PHG currently trades 81.2% from its 52-week high vs BSX's 51.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.66x | 1.12x | 0.55x | 0.34x | 0.47x |
| 52-Week HighHighest price in past year | $293.81 | $33.44 | $404.87 | $109.50 | $106.33 |
| 52-Week LowLowest price in past year | $198.64 | $21.95 | $289.91 | $54.98 | $77.16 |
| % of 52W HighCurrent price vs 52-week peak | +70.4% | +81.2% | +72.7% | +51.7% | +73.3% |
| RSI (14)Momentum oscillator 0–100 | 35.6 | 47.7 | 24.3 | 33.2 | 27.3 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 1.0M | 2.1M | 15.5M | 7.8M |
Analyst Outlook
MDT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: RMD as "Buy", PHG as "Hold", SYK as "Buy", BSX as "Buy", MDT as "Buy". Consensus price targets imply 61.4% upside for BSX (target: $91) vs 35.9% for RMD (target: $281). For income investors, MDT offers the higher dividend yield at 3.57% vs RMD's 1.02%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $281.29 | — | $403.69 | $91.33 | $109.50 |
| # AnalystsCovering analysts | 35 | 22 | 50 | 43 | 49 |
| Dividend YieldAnnual dividend ÷ price | +1.0% | +1.5% | +1.1% | — | +3.6% |
| Dividend StreakConsecutive years of raises | 14 | 1 | 34 | 0 | 36 |
| Dividend / ShareAnnual DPS | $2.11 | $0.34 | $3.36 | — | $2.78 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.0% | 0.0% | 0.0% | 0.0% | +3.2% |
RMD leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PHG leads in 2 (Valuation Metrics, Total Returns). 1 tied.
RMD vs PHG vs SYK vs BSX vs MDT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RMD or PHG or SYK or BSX or MDT a better buy right now?
For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.
9% revenue growth year-over-year, versus -1. 0% for Koninklijke Philips N. V. (PHG). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate ResMed Inc. (RMD) a "Buy" — based on 35 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RMD or PHG or SYK or BSX or MDT?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
6x versus Stryker Corporation at 35. 0x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ResMed Inc. wins at 1. 08x versus Medtronic plc's 36. 00x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — RMD or PHG or SYK or BSX or MDT?
Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +31.
2%, compared to -42. 7% for Koninklijke Philips N. V. (PHG). Over 10 years, the gap is even starker: RMD returned +293. 8% versus MDT's +26. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RMD or PHG or SYK or BSX or MDT?
By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.
34β versus Koninklijke Philips N. V. 's 1. 12β — meaning PHG is approximately 225% more volatile than BSX relative to the S&P 500. On balance sheet safety, ResMed Inc. (RMD) carries a lower debt/equity ratio of 14% versus 74% for Koninklijke Philips N. V. — giving it more financial flexibility in a downturn.
05Which is growing faster — RMD or PHG or SYK or BSX or MDT?
By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.
9% versus -1. 0% for Koninklijke Philips N. V. (PHG). On earnings-per-share growth, the picture is similar: Koninklijke Philips N. V. grew EPS 224. 0% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, BSX leads at 16. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RMD or PHG or SYK or BSX or MDT?
ResMed Inc.
(RMD) is the more profitable company, earning 27. 2% net margin versus 5. 0% for Koninklijke Philips N. V. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus 8. 0% for PHG. At the gross margin level — before operating expenses — BSX leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RMD or PHG or SYK or BSX or MDT more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, ResMed Inc. (RMD) is the more undervalued stock at a PEG of 1. 08x versus Medtronic plc's 36. 00x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 19. 6x for Stryker Corporation — 5. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 61. 4% to $91. 33.
08Which pays a better dividend — RMD or PHG or SYK or BSX or MDT?
In this comparison, MDT (3.
6% yield), PHG (1. 5% yield), SYK (1. 1% yield), RMD (1. 0% yield) pay a dividend. BSX does not pay a meaningful dividend and should not be held primarily for income.
09Is RMD or PHG or SYK or BSX or MDT better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
55), 1. 1% yield, +187. 1% 10Y return). Both have compounded well over 10 years (SYK: +187. 1%, PHG: +48. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RMD and PHG and SYK and BSX and MDT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RMD is a mid-cap quality compounder stock; PHG is a mid-cap quality compounder stock; SYK is a mid-cap quality compounder stock; BSX is a mid-cap high-growth stock; MDT is a mid-cap income-oriented stock. RMD, PHG, SYK, MDT pay a dividend while BSX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.